The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial

Br J Haematol. 2019 May;185(4):791-793. doi: 10.1111/bjh.15629. Epub 2018 Nov 8.
No abstract available

Keywords: chronic myeloid leukaemia; imatinib; lymphocyte subsets; treatment discontinuation; tyrosine kinase inhibitors.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Dasatinib / administration & dosage
  • Drug Administration Schedule
  • Drug Substitution
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Lymphocyte Subsets / drug effects
  • Lymphocyte Subsets / immunology*
  • Protein Kinase Inhibitors / administration & dosage*
  • Pyrimidines / administration & dosage

Substances

  • Antineoplastic Agents
  • BCR-ABL1 fusion protein, human
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib